What Is the Place of Clozapine in the Treatment of Early Psychosis in Canada?

Canadian Journal of Psychiatry

Volumn 62, Issue 2, 2017, Pages 109-114

  Williams, Richard ^a   Malla, Ashok ^b   Roy, Marc Andre ^d,e   Joober, Ridha ^b,c   Manchanda, Rahul ^f,g   Tibbo, Phil ^h,i   Banks, Nicola ^j   Agid, Ofer ^k,l  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^d UNIVERSITÉ LAVAL   (Canada)

^e Family Medicine Center   (Canada)

^f UNIVERSITY OF WESTERN ONTARIO   (Canada)

^g LONDON HEALTH SCIENCES CENTRE   (Canada)

^h DALHOUSIE UNIVERSITY   (Canada)

ⁱ Nova Scotia Early Psychosis Program   (Canada)

^j Canadian Consortium for Early Intervention in Psychosis   (New Zealand)

^k CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^l UNIVERSITY OF TORONTO   (Canada)

more..

Author keywords

clozapine; first episode; treatment resistance psychosis

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

BRIEF PSYCHIATRIC RATING SCALE; CANADA; CLINICAL GLOBAL IMPRESSION SCALE; DISORIENTATION; DRUG USE; EARLY INTERVENTION; HEALTH CARE DELIVERY; HUMAN; OUTCOME ASSESSMENT; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIPSYCHOTIC AGENTS; CANADA; CLOZAPINE; HUMANS; PSYCHOTIC DISORDERS;

EID: 85011552096     PISSN: 07067437     EISSN: 14970015     Source Type: Journal    
DOI: 10.1177/0706743716651049     Document Type: Review

References (50)

1. Harrison G, Hopper K, Craig T, et al. Recovery from psychotic illness: a 15- and 25-year international follow-up study. Br J Psychiatry. 2001; 178: 506-517.
2. Birchwood M, Todd P, Jackson C,. Early intervention in psychosis. The critical period hypothesis. Br J Psychiatry Suppl. 1998; 172 (33): 53-59.
3. McGorry PD, Edwards J, Mihalopoulos C, et al. EPPIC: an evolving system of early detection and optimal management. Schizophr Bull. 1996; 22 (2): 305-326.
4. Malla AM, Norman RM,. Treating psychosis: is there more to early intervention than intervening early? Can J Psychiatry. 2001; 46 (7): 645-648.
5. Iyer S, Jordan G, MacDonald K, et al. Early intervention for psychosis: a Canadian perspective. J Nerv Ment Dis. 2015; 203 (5): 356-364.
6. Bertelsen M, Jeppesen P, Petersen L, et al. Five-year follow-up of a randomized multicenter trial of intensive early intervention vs standard treatment for patients with a first episode of psychotic illness: the OPUS trial. Arch Gen Psychiatry. 2008; 65 (7): 762-771.
7. Malla AK, Norman RM, Joober R,. First-episode psychosis, early intervention, and outcome: what have we learned? Can J Psychiatry. 2005; 50 (14): 881-891.
8. Scholten DJ, Malla AK, Norman RM, et al. Removing barriers to treatment of first-episode psychotic disorders. Can J Psychiatry. 2003; 48 (8): 561-565.
9. Birchwood M, Lester H, McCarthy L, et al. The UK national evaluation of the development and impact of early intervention services (the national EDEN studies): study rationale, design, and baseline characteristics. Early Interv Psychiatry. 2014; 8 (1): 59-67.
10. Malla A, Norman R, Schmitz N, et al. Predictors of rate and time to remission in first-episode psychosis: a two-year outcome study. Psychol Med. 2006; 36 (5): 649-658.
11. Cassidy CM, Norman R, Manchanda R, et al. Testing definitions of symptom remission in first-episode psychosis for prediction of functional outcome at 2 years. Schizophr Bull. 2010; 36 (5): 1001-1008.
12. McGorry P, Johanessen JO, Lewis S, et al. Early intervention in psychosis: keeping faith with evidence-based health care. Psychol Med. 2010; 40 (3): 399-404.
13. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999; 156 (4): 544-549.
14. Robinson DG, Woerner MG, McMeniman, et al. Symptomatic and functional recovery from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161 (3): 473-479.
15. Alvarez-Jimenez M, Priede A, Hetrick SE, et al. Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012; 139 (1-3): 116-128.
16. Jordan G, Lutgens D, Joober R, et al. The relative contribution of cognition and symptomatic remission to functional outcome following treatment of a first episode of psychosis. J Clin Psychiatry. 2014; 75 (6): e566-e572.
17. Windell D, Norman R, Malla AK,. The personal meaning of recovery among individuals treated for a first episode of psychosis. Psychiatr Serv. 2012; 63 (6): 548-553.
18. National Institute for Health and Care Excellence. NICE clinical guideline 82: schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care 2009. Available from: http://www.nice.org.uk/CG082.
19. Kane J, Honigfeld G, Singer J, Meltzer H, Clozaril Collaborative Study Group. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988; 45 (9): 789-796.
20. Chakos M, Leiberman J, Hoffman E, Bradford D, Sheitman B,. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry. 2001; 158 (4): 518-526.
21. Suzuki T, Remington G, Mulsant BH, et al. Defining treatment-resistance schizophrenia and response to antipsychotics: a review and recommendation. Psychiatry Res. 2012; 197 (1-2): 1-6.
22. Conley RR, Kelly DL,. Management of treatment resistance in schizophrenia. Biol Psychiatry 2001; 50 (11): 898-911.
23. Lee J, Takeuchi H, Fervaha G, et al. Subtyping schizophrenia by treatment response: antipsychotic development and the central role of positive symptoms. Can J Psychiatry. 2015; 60 (11): 515-522.
24. Remington G, Agid O, Foussias G, et al. Clozapine's role in the treatment of first-episode schizophrenia. Am J Psychiatry. 2013; 170 (2): 146-151.
25. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust N Z J Psychiatry. 2005; 39 (1-2): 1-30.
26. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB, Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010; 36 (1): 94-103.
27. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004; 161 (2 Suppl): 1-56.
28. Clinical practice guidelines. Treatment of schizophrenia. Can J Psychiatry. 2005; 50 (13 Suppl 1): 7S-57S.
29. Lewis SW, Barnes TRE, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophren Bull. 2006; 32 (4): 715-723.
30. Samara MT, Dold M, Gianatsi M, et al. Efficacy, acceptability, and tolerability of antipsychotics in treatment-resistance schizophrenia: a network meta-analysis. JAMA Psychiatry. 2016; 73 (3): 199-210.
31. Agid O, Remington G, Kapur S, et al. Early use of clozapine for poorly responding first-episode psychosis. J Clin Psychopharmacol. 2007; 27 (4): 369-373.
32. Agid O, Arenovich T, Sajeev G, et al. An algorithm-based approach to first-episode schizophrenia: response rates over 3 prospective antipsychotic trials with a retrospective data analysis. J Clin Psychiatry. 2011; 72 (11): 1439-1444.
33. Meltzer HY,. Suicide in schizophrenia: risk factors and clozapine treatment. J Clin Psychiatry. 1998; 59 (Suppl 3): 15-20.
34. Machielsen M, Beduin AS, Dekker N, et al. Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. J Psychopharmacol. 2012; 26 (1): 189-195.
35. Horvitz-Lennon M, Donohue JM, Domino ME, Normand SL,. Improving quality and diffusing best practices: the case of schizophrenia. Health Aff (Millwood) 2009; 28 (3): 701-12.
36. Latimer E, Wynant W, Clark R, et al. Underprescribing of clozapine and unexplained variation in use across hospitals and regions in the Canadian province of Québec. Clin Schizophr Relat Psychoses. 2013; 7 (1): 33-41.
37. Wheeler AJ,. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand. Ann Pharmacother. 2008; 42 (6): 852-860.
38. Alvir JM, Lieberman JA, Safferman AZ, et al. Clozapine-induced agranulosytosis. Incidence and risk factors in the United States. N Engl J Med. 1993; 329 (3): 162-167.
39. Honigfeld G, Arellano F, Sethi J, et al. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry. 1998; 59 (Suppl 3): 3-7.
40. Munro J, O'Sullivan D, Andrews C, et al. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance. Br J Psychiatry. 1999; 175: 576-580.
41. Atkin K, Kendall F, Gould D, et al. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry. 1996; 169 (4): 483-488.
42. Asenjo Lobos C, Komossa K, Rummel-Kluge C, et al. Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev. 2010; 10 (11): CD006633.
43. Cohen D, Bogers JP, van Dijk D, et al. Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy. J Clin Psychiatry. 2012; 73 (10): 1307-1312.
44. Iyer S, Banks N, Roy MA, et al. A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part II-physician perspectives. Can J Psychiatry. 2013; 58 (5 Suppl 1): 23S-29S.
45. Mortimer AM, Singh P, Shepherd CJ, Puthiryackal J,. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world. Clin Schizophr Relat Psychoses. 2010; 4 (1): 49-55.
46. Bodnar M, Malla A, Joober R, Lepage M,. Cognitive markers of short-term clinical outcome in first-episode psychosis. Br J Psychiatry. 2008; 193 (4): 297-304.
47. Bodnar M, Harvey PO, Malla AK, et al. The parahippocampal gyrus as a neural marker of early remission in first-episode psychosis: a voxel-based morphometry study. Clin Schizophr Related Psychoses. 2011; 4 (4): 217-228.
48. Procter EK, Landsverk J, Aarons G, et al. Implementation research in mental health services: an emerging science with conceptual, methodological, and training challenges. Adm Policy Ment Health. 2009; 36 (1): 24-34.
49. McHugh RK, Barlow DH,. The dissemination and implementation of evidence-based psychological treatments. A review of current efforts. Am Psychol. 2010; 65 (2): 73-84.
50. Pope MA, Joober R, Malla AK,. Diagnostic stability of first-episode psychotic disorders and persistence of comorbid psychiatric disorders over 1 year. Can J Psychiatry. 2013; 58 (10): 588-94.